IL4 and asthma: Whilst biologic therapies targeting the type-2 cytokines IL-4, -5, -13 or epithelial alarmins are proving transformative in the management of severe type-2 high asthma (Holguin et al., 2020), for those with type-2 low inflammation, treatment options remain limited and pathology poorly understood (Hinks et al, 2021).